Akums Drugs and Pharmaceuticals Limited (BOM:544222)
India · Delayed Price · Currency is INR 450.65
-13.70 (-2.95%)
At close: Feb 13, 2026
BOM:544222 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 42,567 | 41,182 | 41,782 | 36,548 | 36,719 | 27,226 |
Other Revenue | 618.2 | 29.73 | 34.8 | 23.7 | 33.29 | 35.83 |
Revenue | 43,185 | 41,211 | 41,817 | 36,572 | 36,752 | 27,262 |
Revenue Growth (YoY) | 7.69% | -1.45% | 14.34% | -0.49% | 34.81% | - |
Cost of Revenue | 25,580 | 24,993 | 26,204 | 23,493 | 24,145 | 17,343 |
Gross Profit | 17,605 | 16,218 | 15,613 | 13,079 | 12,607 | 9,919 |
Selling, General & Admin | 7,801 | 7,573 | 6,918 | 6,291 | 5,399 | 4,541 |
Other Operating Expenses | 4,460 | 3,926 | 3,793 | 3,765 | 3,104 | 2,424 |
Operating Expenses | 13,806 | 13,034 | 11,967 | 11,184 | 9,449 | 7,663 |
Operating Income | 3,799 | 3,185 | 3,646 | 1,895 | 3,158 | 2,256 |
Interest Expense | -705.3 | -304.07 | -502.51 | -459.73 | -163.38 | -63.88 |
Interest & Investment Income | 249.86 | 249.86 | 119.99 | 78.8 | 46.31 | 61.44 |
Earnings From Equity Investments | - | - | - | -2.03 | 2.03 | 3.47 |
Currency Exchange Gain (Loss) | 41.65 | 41.65 | 72.05 | -38.93 | 26.46 | 27.36 |
Other Non Operating Income (Expenses) | -41.93 | -3.26 | -3,581 | 490.16 | -4,883 | -490.62 |
EBT Excluding Unusual Items | 3,344 | 3,169 | -246.18 | 1,963 | -1,813 | 1,794 |
Impairment of Goodwill | - | - | - | - | -129.77 | -100 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.77 |
Gain (Loss) on Sale of Assets | -1.12 | -1.12 | -3.17 | 45.75 | -20.66 | -4.04 |
Asset Writedown | 38.27 | 38.27 | 1.38 | -722.64 | 10.55 | - |
Other Unusual Items | -20.57 | 246.51 | -204.81 | 216.81 | 21 | 32.16 |
Pretax Income | 3,360 | 3,453 | -452.78 | 1,503 | -1,932 | 1,723 |
Income Tax Expense | 113.6 | 14.76 | -460.68 | 524.8 | 576.77 | 488.26 |
Earnings From Continuing Operations | 3,247 | 3,438 | 7.9 | 978.17 | -2,509 | 1,234 |
Minority Interest in Earnings | -64.69 | -56.01 | -48.25 | -29.62 | -16.62 | -7.3 |
Net Income | 3,182 | 3,382 | -40.35 | 948.55 | -2,525 | 1,227 |
Net Income to Common | 3,182 | 3,382 | -40.35 | 948.55 | -2,525 | 1,227 |
Shares Outstanding (Basic) | 153 | 150 | 143 | 143 | 143 | 143 |
Shares Outstanding (Diluted) | 153 | 150 | 143 | 143 | 143 | 143 |
Shares Change (YoY) | 4.01% | 4.58% | - | - | - | - |
EPS (Basic) | 20.78 | 22.60 | -0.28 | 6.63 | -17.65 | 8.58 |
EPS (Diluted) | 20.78 | 22.60 | -0.28 | 6.63 | -17.65 | 8.58 |
Free Cash Flow | - | 1,929 | 1,869 | -1,522 | -2,257 | 478.04 |
Free Cash Flow Per Share | - | 12.89 | 13.06 | -10.64 | -15.78 | 3.34 |
Gross Margin | 40.77% | 39.35% | 37.34% | 35.76% | 34.30% | 36.38% |
Operating Margin | 8.80% | 7.73% | 8.72% | 5.18% | 8.59% | 8.28% |
Profit Margin | 7.37% | 8.21% | -0.10% | 2.59% | -6.87% | 4.50% |
Free Cash Flow Margin | - | 4.68% | 4.47% | -4.16% | -6.14% | 1.75% |
EBITDA | 5,364 | 4,568 | 4,788 | 2,908 | 4,005 | 2,880 |
EBITDA Margin | 12.42% | 11.09% | 11.45% | 7.95% | 10.90% | 10.57% |
D&A For EBITDA | 1,564 | 1,383 | 1,142 | 1,013 | 846.75 | 624.48 |
EBIT | 3,799 | 3,185 | 3,646 | 1,895 | 3,158 | 2,256 |
EBIT Margin | 8.80% | 7.73% | 8.72% | 5.18% | 8.59% | 8.28% |
Effective Tax Rate | 3.38% | 0.43% | - | 34.92% | - | 28.34% |
Revenue as Reported | 43,677 | 41,703 | 42,122 | 37,009 | 36,945 | 27,438 |
Advertising Expenses | - | 394.17 | 389.87 | 354.65 | 294.51 | 257.82 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.